Sirolimus-loaded exosomes as a promising vascular delivery system for the prevention of post-angioplasty restenosis

Mehryab, Fatemeh; Rabbani, Shahram; Shekari, Faezeh; Nazari, Abdoreza; Goshtasbi, Nazanin; Haeri, Azadeh

doi:10.1007/s13346-023-01390-z

Cited by 3 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models, such as mice and rats, possess similar physiologies to humans and are generally cost-effective and easily managed. Usually, researchers administer drug-loaded exosomes into these testing animals, then they monitor the biodistribution of the drugloaded exosomes and observe the effects on the animals, including physiological and behavioral changes as well as histological effects [104][105][106][107]. The use of small animal models thus allows for controlled evaluation of drug-loaded exosomes before advancing to human testing.…”

Section: Animal Experimentsmentioning

confidence: 99%

Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review

Chen,

Xiong,

Tian

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Exosomes are nanoscale extracellular vesicles secreted by cells and enclosed by a lipid bilayer membrane containing various biologically active cargoes such as proteins, lipids, and nucleic acids. Engineered exosomes generated through genetic modification of parent cells show promise as drug delivery vehicles, and they have been demonstrated to have great therapeutic potential for treating cancer, cardiovascular, neurological, and immune diseases, but systematic knowledge is lacking regarding optimization of drug loading and assessment of delivery efficacy. This review summarizes current approaches for engineering exosomes and evaluating their drug delivery effects, and current techniques for assessing exosome drug loading and release kinetics, cell targeting, biodistribution, pharmacokinetics, and therapeutic outcomes are critically examined. Additionally, this review synthesizes the latest applications of exosome engineering and drug delivery in clinical translation. The knowledge compiled in this review provides a framework for the rational design and rigorous assessment of exosomes as therapeutics. Continued advancement of robust characterization methods and reporting standards will accelerate the development of exosome engineering technologies and pave the way for clinical studies. Graphical Abstract

show abstract

Section: Animal Experimentsmentioning

confidence: 99%

Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review

Chen,

Xiong,

Tian

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…In another application, sirolimus (SIR), an mTOR inhibitor, was encapsulated within exosomes derived from fibroblasts and used in the treatment of restenosis. The outcomes revealed a notable decrease in Ki67, alpha-smooth muscle actin (α-SMA), and matrix metalloproteinase (MMP) markers in the arteries, effectively preventing restenosis [109]. Moreover, EVs derived from immune cells can be loaded with immunomodulatory agents to enhance the anti-tumor immune response, making them potential candidates for immunotherapy in glioblastoma.…”

Section: Extracellular Vesicle As Drug Delivery Vehiclementioning

confidence: 99%

Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment

Singh,

Barik,

Lawrie

et al. 2023

IJMS

View full text Add to dashboard Cite

The mTOR signaling pathway plays a pivotal and intricate role in the pathogenesis of glioblastoma, driving tumorigenesis and proliferation. Mutations or deletions in the PTEN gene constitutively activate the mTOR pathway by expressing growth factors EGF and PDGF, which activate their respective receptor pathways (e.g., EGFR and PDGFR). The convergence of signaling pathways, such as the PI3K-AKT pathway, intensifies the effect of mTOR activity. The inhibition of mTOR has the potential to disrupt diverse oncogenic processes and improve patient outcomes. However, the complexity of the mTOR signaling, off-target effects, cytotoxicity, suboptimal pharmacokinetics, and drug resistance of the mTOR inhibitors pose ongoing challenges in effectively targeting glioblastoma. Identifying innovative treatment strategies to address these challenges is vital for advancing the field of glioblastoma therapeutics. This review discusses the potential targets of mTOR signaling and the strategies of target-specific mTOR inhibitor development, optimized drug delivery system, and the implementation of personalized treatment approaches to mitigate the complications of mTOR inhibitors. The exploration of precise mTOR-targeted therapies ultimately offers elevated therapeutic outcomes and the development of more effective strategies to combat the deadliest form of adult brain cancer and transform the landscape of glioblastoma therapy.

show abstract

Extracellular vesicle-based formulation of doxorubicin: drug loading optimization, characterization, and cytotoxicity evaluation in tumor spheroids

Mehryab,

Ebrahimi,

Baharvand

et al. 2024

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

Sirolimus-loaded exosomes as a promising vascular delivery system for the prevention of post-angioplasty restenosis

Cited by 3 publications

References 65 publications

Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review

Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review

Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment

Extracellular vesicle-based formulation of doxorubicin: drug loading optimization, characterization, and cytotoxicity evaluation in tumor spheroids

Contact Info

Product

Resources

About